Skip to main content
. 2021 Jan 4;13(1):137. doi: 10.3390/cancers13010137

Figure 1.

Figure 1

Schematic representation of pathways currently under investigations as actionable therapeutic targets harnessing BRAFV600E mutant metastatic colorectal cancer (mCRC). Legend: mAb = monoclonal antibodies; i = inhibitor. Vit = vitamin. Mut = mutation.